Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)
Not Applicable
Terminated
- Conditions
- Lung Infection
- Registration Number
- NCT02173613
- Lead Sponsor
- University Hospital, Grenoble
- Brief Summary
The main objective is to evaluate the interest of the repeated measurement of procalcitonin in patients with pulmonary infection to reduce the duration of antibiotic therapy in comparison with a conventional clinical strategy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 117
Inclusion Criteria
- Age ≥ 80 years
- Started antibiotics for a chest infection
- Procalcitonin performed J0 antibiotic treatment
- Person affiliated to the social security
Exclusion Criteria
- Patients with a documented infection with germs after Listeria spp, Legionella pneumophilia, Mycobacterium tuberculosis
- Patients with a documented infection with a virus or parasite (eg hemorrhagic fever, malaria)
- Patients with endovascular infection associated (endocarditis, pacemaker. Intravascular catheter)
- Patients with lung abscess associated upon entry Patients with a chronic infection associated
- Patients with severe immunosuppression (HIV or transplant)
- Palliative patient
- Death within 24 hours of admission to nursing units.
- Presence of antibiotic treatment for chronic infection.
- Patient under guardianship, curatorship or any other administrative or judicial action or deprivation of the right or freedom
- Patients hospitalized without their consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Duration of antibiotic therapy Success of antibiotic therapy within 45 days of inclusion
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link procalcitonin levels to reduced antibiotic duration in elderly lung infection patients?
How does procalcitonin-guided de-escalation compare to standard-of-care antibiotic strategies in hospitalized elderly with community-acquired pneumonia?
Which biomarkers correlate with successful procalcitonin-targeted antibiotic reduction in NCT02173613?
What adverse events are associated with procalcitonin-guided antibiotic de-escalation in elderly populations?
Are there alternative biomarkers or drugs to procalcitonin for optimizing antibiotic therapy in geriatric respiratory infections?
Trial Locations
- Locations (1)
University Hospital Grenoble
🇫🇷Grenoble, Rhone Alpes, France
University Hospital Grenoble🇫🇷Grenoble, Rhone Alpes, France